Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN016HC in Advanced Malignant Solid Tumors
NCT07475559Phase 1Not yet recruiting
- Sponsor
- Alphamab Oncology
- Start
- Mar 2026
- Primary completion
- Jul 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JSKN016HC in advanced malignant solid tumor, sponsored by Alphamab Oncology. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 2 years and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JSKN016HC
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT07475559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475559.